Phase iii clinical trials clinical trials phase ii as topic. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy1

Cell Line, Tumor

Diseases31

Neoplasms Breast Neoplasms Lung Neoplasms Disease Progression Neoplasm Metastasis Neoplasm Recurrence, Local Prostatic Neoplasms Carcinoma, Non-Small-Cell Lung Neutropenia Nausea Recurrence Colorectal Neoplasms Leukopenia Drug-Related Side Effects and Adverse Reactions Melanoma Vomiting Brain Neoplasms Ovarian Neoplasms Thrombocytopenia Stroke HIV Infections Fatigue Kidney Neoplasms Hematologic Diseases Acute Disease Pain Carcinoma, Small Cell Head and Neck Neoplasms Carcinoma, Renal Cell Carcinoma, Squamous Cell Pancreatic Neoplasms

Chemicals and Drugs48

Antineoplastic Agents Antisickling Agents Antibodies, Monoclonal, Humanized Cisplatin Antibodies, Monoclonal Placebos Deoxycytidine Cancer Vaccines Fluorouracil Paclitaxel Taxoids Carboplatin Vinblastine Organoplatinum Compounds Antineoplastic Agents, Phytogenic Doxorubicin Drugs, Investigational Antimetabolites, Antineoplastic Camptothecin Leucovorin Cyclophosphamide Quinazolines Dacarbazine Drug Combinations Etoposide Epirubicin Vincristine Angiogenesis Inhibitors Antineoplastic Agents, Alkylating Benzenesulfonates Niacinamide Phenylurea Compounds Methotrexate Pyrroles Recombinant Proteins Protein Kinase Inhibitors Prednisone Ifosfamide Thiophenes Tumor Markers, Biological Biological Markers Tegafur Pyridines Antineoplastic Agents, Hormonal Pyrimidines Interferon-alpha Thalidomide Epothilones

Analytical, Diagnostic and Therapeutic Techniques and Equipment67

Clinical Trials, Phase III as Topic Clinical Trials as Topic Clinical Trials, Phase II as Topic Clinical Trials, Phase IV as Topic Treatment Outcome Randomized Controlled Trials as Topic Clinical Trials, Phase I as Topic Research Design Double-Blind Method Multicenter Studies as Topic Antineoplastic Combined Chemotherapy Protocols Endpoint Determination Disease-Free Survival Survival Analysis Combined Modality Therapy Drug Administration Schedule Immunotherapy Survival Rate Chemotherapy, Adjuvant Prospective Studies Patient Selection Prognosis Controlled Clinical Trials as Topic Administration, Oral Placebos Drug Evaluation, Preclinical Neoplasm Staging Infusions, Intravenous Follow-Up Studies Clinical Protocols Drug Evaluation Early Termination of Clinical Trials Single-Blind Method Drug Therapy, Combination Sample Size Kaplan-Meier Estimate Pilot Projects Severity of Illness Index Maximum Tolerated Dose Feasibility Studies Treatment Failure Risk Factors Remission Induction Risk Assessment Questionnaires Reproducibility of Results Drug Approval Meta-Analysis as Topic Salvage Therapy Data Interpretation, Statistical Neoadjuvant Therapy Cross-Over Studies Random Allocation Proportional Hazards Models Radiotherapy, Adjuvant Pain Measurement Retrospective Studies Molecular Targeted Therapy Analysis of Variance Predictive Value of Tests Phytotherapy Statistics, Nonparametric Injections, Intravenous Exercise Therapy Multivariate Analysis Injections, Subcutaneous Therapeutic Human Experimentation

Psychiatry and Psychology2

Patient Compliance Pain

Phenomena and Processes7

Time Factors Dose-Response Relationship, Drug Metabolic Detoxication, Phase II Maximum Tolerated Dose Drug Resistance, Neoplasm Pain Myoelectric Complex, Migrating

Disciplines and Occupations6

Research Design Evidence-Based Medicine Medical Oncology Outcome Assessment (Health Care)Biomedical Research Therapeutic Human Experimentation

Anthropology, Education, Sociology and Social Phenomena7

Quality of Life Drug Approval Informed Consent Patient Education as Topic United States Food and Drug Administration National Cancer Institute (U.S.)National Institutes of Health (U.S.)

Technology, Industry, Agriculture2

Dietary Supplements Drug Industry

Humanities1

Quality of Life

Information Science5

Survival Rate Questionnaires Periodicals as Topic Data Interpretation, Statistical Review Literature as Topic

Named Groups1

Research Subjects

Health Care58

Clinical Trials, Phase III as Topic Clinical Trials as Topic Clinical Trials, Phase II as Topic Clinical Trials, Phase IV as Topic Treatment Outcome Randomized Controlled Trials as Topic Clinical Trials, Phase I as Topic Double-Blind Method Multicenter Studies as Topic Disease-Free Survival Survival Analysis Survival Rate Prospective Studies Patient Selection Controlled Clinical Trials as Topic Follow-Up Studies Clinical Protocols Early Termination of Clinical Trials Single-Blind Method Clinical Trials Data Monitoring Committees Sample Size Kaplan-Meier Estimate Pilot Projects Severity of Illness Index Feasibility Studies Cost-Benefit Analysis Outcome Assessment (Health Care)Treatment Failure Risk Factors Risk Assessment Questionnaires Reproducibility of Results Patient Compliance Guidelines as Topic Meta-Analysis as Topic Safety Data Interpretation, Statistical Congresses as Topic Cross-Over Studies Informed Consent Practice Guidelines as Topic Patient Education as Topic Random Allocation United States Food and Drug Administration Proportional Hazards Models National Cancer Institute (U.S.)Retrospective Studies Placebo Effect Patient Participation Intention to Treat Analysis Analysis of Variance Predictive Value of Tests Research Support as Topic Statistics, Nonparametric National Institutes of Health (U.S.)Multivariate Analysis Patient Satisfaction Bias (Epidemiology)

Publication Characteristics1

Clinical Trial, Phase III

Geographicals2

United States Europe

Anatomy Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Humanities Information Science Named Groups Health Care Publication Characteristics Geographicals

Clinical Trials, Phase III as Topic Clinical Trial, Phase III Clinical Trials as Topic Clinical Trials, Phase II as Topic Clinical Trials, Phase IV as Topic Treatment Outcome Antineoplastic Agents Randomized Controlled Trials as Topic Clinical Trials, Phase I as Topic Research Design Double-Blind Method Antisickling Agents Multicenter Studies as Topic Antineoplastic Combined Chemotherapy Protocols Endpoint Determination Neoplasms Disease-Free Survival Antibodies, Monoclonal, Humanized Time Factors Cisplatin Survival Analysis Combined Modality Therapy Drug Administration Schedule Breast Neoplasms Immunotherapy Lung Neoplasms Disease Progression Survival Rate Dose-Response Relationship, Drug Chemotherapy, Adjuvant Prospective Studies Antibodies, Monoclonal Patient Selection United States Prognosis Controlled Clinical Trials as Topic Administration, Oral Placebos Drug Evaluation, Preclinical Cell Line, Tumor Neoplasm Staging Neoplasm Metastasis Deoxycytidine Infusions, Intravenous Cancer Vaccines Neoplasm Recurrence, Local Fluorouracil Follow-Up Studies Paclitaxel Taxoids Metabolic Detoxication, Phase II Clinical Protocols Quality of Life Prostatic Neoplasms Drug Evaluation Early Termination of Clinical Trials Single-Blind Method Clinical Trials Data Monitoring Committees Drug Therapy, Combination Sample Size Carcinoma, Non-Small-Cell Lung Carboplatin Kaplan-Meier Estimate Pilot Projects Vinblastine Organoplatinum Compounds Evidence-Based Medicine Antineoplastic Agents, Phytogenic Doxorubicin Drugs, Investigational Antimetabolites, Antineoplastic Camptothecin Neutropenia Leucovorin Severity of Illness Index Nausea Medical Oncology Maximum Tolerated Dose Cyclophosphamide Feasibility Studies Recurrence Cost-Benefit Analysis Outcome Assessment (Health Care)Colorectal Neoplasms Treatment Failure Risk Factors Quinazolines Remission Induction Research Subjects Risk Assessment Questionnaires Biomedical Research Dacarbazine Reproducibility of Results Patient Compliance Leukopenia Drug Combinations Drug Approval Etoposide Drug-Related Side Effects and Adverse Reactions

No FAQ available that match "phase iii clinical trials clinical trials phase ii as topic"